Integra LifeSciences (NASDAQ:IART) Updates Q4 2024 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided EPS guidance of 0.810-0.890 for the period, compared to the consensus EPS estimate of 0.870. The company issued revenue guidance of $441.0 million-$451.0 million, compared to the consensus revenue estimate of $448.5 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Analysts Set New Price Targets

A number of research analysts have recently commented on IART shares. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Bank of America cut their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Morgan Stanley boosted their target price on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Finally, JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $27.25.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $26.70 on Thursday. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The stock has a 50 day simple moving average of $18.90 and a 200 day simple moving average of $24.40. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.42. The stock has a market cap of $2.07 billion, a P/E ratio of -296.67, a PEG ratio of 0.82 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.25% and a negative net margin of 0.42%. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter last year, the firm earned $0.76 earnings per share. The company’s revenue was down .4% on a year-over-year basis. Research analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.